StockData

American Well vs OptimizeRx

AMWL and OPRX side by side, both in miscellaneous business services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AMWL and OPRX compare

American Well is the larger company, worth 1.5 times as much as OptimizeRx ($193M against $125M).

OptimizeRx grew revenue faster over the last twelve months (−5.8% versus −19.0% for American Well).

OptimizeRx keeps more of each dollar of sales as profit, with a net margin of 4.7% compared with −35.7% at American Well.

American Well scores higher on the StockData Score (11 against 10 for OptimizeRx), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAMWLOPRX
Size and price
Market cap$193M$125M
Share price$11.34$6.64
Change, 1 year184%−57.1%
Change, 5 years−91.5%−90.3%
Beta (5Y)1.841.56
Employees562104
StockData Score
Total score11 (better)10
Valuation score33
Growth score22
Performance score12 (better)
Health score5 (better)3
Dividend score00
Valuation
P/E–27.7×
P/S0.9× (better)1.3×
P/B0.9× (better)1.0×
EV/EBITDA–7.9×
P/FCF–6.8×
FCF yield−13.7%14.7% (better)
Fair value$18.90$10.13
Margin of safety40.0% (better)34.5%
Growth
Revenue growth (TTM)−19.0%−5.8% (better)
Revenue growth, 5Y average0.33%20.4% (better)
Profitability
Gross margin51.9%73.2% (better)
Operating margin−37.3%11.1% (better)
Net margin−35.7%4.7% (better)
FCF margin−12.1%18.6% (better)
Return on equity−31.0%3.7% (better)
Return on invested capital−145%5.8% (better)
Financial health
Debt / equity0.000.15 (better)
Net debt / EBITDA–−0.33
Interest coverage–2.3×
Current ratio2.905.58 (better)
Altman Z-score−7.182.72 (better)
Piotroski F-score68 (better)
Dividends and buybacks
Buyback yield0.00%–
Shareholder yield0.00% (better)0.00%
Ownership
Held by institutions42.3%59.6%
Held by insiders15.8%19.4%
Insider net buying, 12 months−$1.0M−$18.8K (better)
Short interest, % of float1.7%7.8%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.